Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$14.23 USD
+0.82 (6.11%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $14.25 +0.02 (0.14%) 7:44 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
DAWN 14.23 +0.82(6.11%)
Will DAWN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DAWN
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength
Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet
Other News for DAWN
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
Day One Biopharmaceuticals added to Analyst Focus List at JPMorgan
Day One Biopharmaceuticals Breaks Below 200-Day Moving Average - Notable for DAWN
Day One Biopharma draws double upgrade at BofA on Ojemda potential
Etsy downgraded, Carvana upgraded: Wall Street's top analyst calls